Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 1;60(5):1470-1477.
doi: 10.1167/iovs.18-26422.

The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration

Emily E Brown  1   2 , Jacob D Ball  3 , Zhaoyi Chen  3 , Gibran S Khurshid  1 , Mattia Prosperi  3 , John D Ash  1
Affiliations

The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration

Emily E Brown et al. Invest Ophthalmol Vis Sci. .

Abstract

Purpose: AMD is the leading cause of irreversible blindness in older individuals in the Western world, and there are currently no therapies to halt disease progression. Studies suggest that the commonly prescribed antidiabetic drug, metformin, is associated with decreased risk of several ocular diseases, but no work has investigated the effect of metformin use on development of AMD. Thus, we aim to investigate whether metformin use is associated with decreased risk of developing AMD.

Methods: In this retrospective case-control study, we used medical records from patients older than 55 who have visited a University of Florida health clinic. Three controls were matched for every AMD case, defined by International Classification of Diseases, Ninth Revision code, based on the Charlson Comorbidity Index to ensure comparable baseline overall health status. Univariate and conditional multivariable logistic regressions were used to determine the association between a variety of covariates, including metformin use, and AMD diagnosis.

Results: Metformin use was associated with decreased odds of developing AMD, independently of the other covariates investigated, with an odds ratio of 0.58 and a 95% confidence interval of 0.43 to 0.79. Other medications assessed were not associated with decreased odds of developing AMD.

Conclusions: Patients who had taken metformin had decreased odds of developing AMD, suggesting that metformin may have a therapeutic role in AMD development or progression in those who are at risk. Further work should include clinical trials to investigate prospectively whether metformin has a protective effect in those at risk for developing AMD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of PSs between cases and controls before and after matching on age (mean), CCI, hypertension (%), and anemia (%).
Figure 2
Figure 2
Population: cases and controls and metformin use with number of patients and percentage of total of previous group for each arm.
See this image and copyright information in PMC

References

    1. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol. 1980;24(suppl):335–610. - PubMed
    1. Lim JY, Lee SY, Kim JG, Lee JY, Chung H, Yoon YH. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012;90:61–67. - PubMed
    1. Malgorzata F. Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations. Klin Oczna. 2010;112:213–216. - PubMed
    1. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122–129. - PMC - PubMed
    1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436. - PMC - PubMed

Publication types